Von Hippel Lindau Antibody (AT82B10) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-04355

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Applications

ELISA, Immunocytochemistry/ Immunofluorescence, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2b Kappa Clone # AT82B10

Format

BSA Free

Concentration

1.0 mg/ml

View all VHL Antibodies »

Product Summary for Von Hippel Lindau Antibody (AT82B10) - BSA Free

Immunogen

Recombinant human Von Hippel Lindau (1-154 aa) purified from E. coli

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2b Kappa

Scientific Data Images for Von Hippel Lindau Antibody (AT82B10) - BSA Free

Western Blot: Von Hippel Lindau Antibody (AT82B10)BSA Free [NBP1-04355]

Western Blot: Von Hippel Lindau Antibody (AT82B10)BSA Free [NBP1-04355]

Western Blot: Von Hippel Lindau Antibody (52A11) [NBP1-04355] - HepG2 cell lysate was resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human VHL antibody (1:500). Protein was visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.

Applications for Von Hippel Lindau Antibody (AT82B10) - BSA Free

Application
Recommended Usage

ELISA

1:100-1:2000

Western Blot

1:500-1:1000
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH 7.4), 10% Glycerol

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: VHL

Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet (beta-domain) and a smaller alpha-helical domain (alpha-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).

Long Name

Von Hippel-Lindau Tumor Suppressor

Alternate Names

Protein G7, pVHL

Gene Symbol

VHL

UniProt

NP_000542

Additional VHL Products

Product Documents for Von Hippel Lindau Antibody (AT82B10) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for Von Hippel Lindau Antibody (AT82B10) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.